Mental Disorders Clinical Trial
Official title:
The Sustained Effects of Ketamine
NCT number | NCT02708849 |
Other study ID # | 1501015203 |
Secondary ID | |
Status | Terminated |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | June 2015 |
Est. completion date | March 2020 |
Verified date | June 2020 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to characterize the effects of a single, sub-anesthetic dose of ketamine in rs-fMRI in healthy subjects. Post-ketamine rs-fMRI data will demonstrate a pattern of increased global brain connectivity (GBC) in fronto-temporal cortex.
Status | Terminated |
Enrollment | 3 |
Est. completion date | March 2020 |
Est. primary completion date | March 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Male or female between the ages of 21-65 years. Females will be included if they are not pregnant and agreed to utilize a barrier method contraceptive (e.g., condom or diaphragm with spermicide) tubal ligation, abstinence, or partner with vasectomy) or if post-menopausal for at least 1 year, or surgically sterile. - Able to provide written informed consent according to Yale HIC guidelines. - Agree to refrain from elective surgeries (including dental) for a 2-week period following study drug. - Able to read and write English as a primary language. Exclusion Criteria: - Personal history of mood, anxiety, or psychotic axis I DSM-IV disorders confirmed after comprehensive psychiatric evaluation. - Any history of serious medical or neurological illness. - Any signs of major medical or neurological illness on examination or as a result of ECG screening or laboratory studies. - A first-degree family member with history of schizophrenia. - Lifetime history of psychoactive substance or alcohol dependence or substance or alcohol abuse (other than nicotine or caffeine abuse), or drinking more that 5 drinks/week during the last year. - Abnormality on physical examination. A subject with a clinical abnormality may be included only if the study physician considers the abnormality will not introduce additional risk factors and will not interfere with the study procedure (e.g. uncontrolled hypertension, hyperthyroidism, or hypothyroidism will be excluded). - A positive pre-study (screening) urine drug screen or, at the study physician's discretion on any drug screens given before the scans. - Pregnant or lactating women or a positive urine pregnancy test for women of child-bearing potential at screening or prior to any imaging day. - Positive HIV or Hepatitis B/C tests. This test will take place at the screening visit. Subjects will be invited back either for their next study visit or for a HIV/Hep debriefing session. A study clinician will inform them in person of the results. They will be given access to counselling and advised of the appropriate next steps. - Has received either prescribed or over-the-counter (OTC) centrally active medicine or herbal supplements within the week prior to the MRI scan. Subjects who have taken OTC medication or herbal supplements may still be entered into the study, if, in the opinion of the principal/co-investigator, the medication received will not interfere with the study procedures or compromise safety. - Any history indicating learning disability, mental retardation, or attention deficit disorder. - Known sensitivity to ketamine. - Known sensitivity to lamotrigine. - Body weight of 250 pounds or greater. - History of claustrophobia. - Presence of cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies in vulnerable positions as assessed by a standard pre-MRI screening questionnaire. - Donation of blood in excess of 500 mL within 56 days prior to dosing. - History of sensitivity to heparin or heparin-induced thrombocytopenia. - Resting blood pressure lower than 90/60 or higher than 150/90, or resting heart rate lower than 45/min or higher than 100/min. |
Country | Name | City | State |
---|---|---|---|
United States | Yale Center for Clinical Investigation, Yale University | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Post-Ketamine Rs-fMRI Data | 24 hours post infusion fMRI data | 24 hours | |
Primary | Global Brain Connectivity | Participants will be randomized into one of two parallel groups—ketamine+lamotrigine or ketamine+placebo—and will complete pre- and post-ketamine rs-fMRI. The hypothesis is that post-ketamine rs-fMRI data will demonstrate a pattern of increased global brain connectivity (GBC) in fronto-temporal cortex. Insufficient number of participants for data collection. |
24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
Recruiting |
NCT06012149 -
Braining: Implementation of Physical Exercise for Patients in Specialist Psychiatry
|
N/A | |
Recruiting |
NCT03222375 -
SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
|
N/A | |
Active, not recruiting |
NCT02836080 -
Integrated Collaborative Care Teams for Youth With Mental Health and/or Addiction Challenges (YouthCan IMPACT)
|
N/A | |
Active, not recruiting |
NCT02907658 -
Efficacy of Internet Use Disorder Prevention
|
N/A | |
Completed |
NCT02710344 -
Using Telehealth to Improve Psychiatric Symptom Management
|
N/A | |
Enrolling by invitation |
NCT02487888 -
A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Active, not recruiting |
NCT02761733 -
The Effectiveness of a Decision-Support Tool for Adult Consumers With Mental Health Needs and Their Care Managers
|
N/A | |
Completed |
NCT01947283 -
Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation
|
N/A | |
Completed |
NCT01633138 -
Performance-based Reinforcement to Enhance Cognitive Remediation Therapy
|
N/A | |
Completed |
NCT01690013 -
Life Quality and Health in Patients With Klinefelter Syndrome
|
N/A | |
Completed |
NCT01656707 -
Adaptive Treatment for Adolescent Cannabis Use Disorders
|
N/A | |
Completed |
NCT01415323 -
Agitation in the Acute Psychiatric Department
|
||
Completed |
NCT01701765 -
Outcomes and Discharge of Long-stay Psychiatric Patients
|
N/A | |
Completed |
NCT00375167 -
Efficacy of the Recovery Workbook as a Psychoeducational Tool for Facilitating Recovery
|
N/A | |
Terminated |
NCT00757497 -
Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia
|
Phase 1 | |
Terminated |
NCT03527550 -
Cognitive Control Training for Urgency in a Naturalistic Clinical Setting
|
N/A | |
Withdrawn |
NCT03518996 -
Non-Invasive Brain Stimulation and Delirium
|
N/A |